A Study of CodaLytic, an Intratumoral Oncolytic Virus, in Patients With Breast Cancer
Key facts
- Who runs it
- Codagenix, Inc
- Where
- Boston and Canton, United StatesSee the 2 sites
- Trial code
- Status
- Withdrawn
- Phase
- Phase 1
- Started
- 15 Jan 2023
- Ended
- 30 Jan 2025
- Type of study
- Interventional, 4 groups
- Treatments tested
- CodaLytic
- Record updated
- 18 October 2023
- Why it stopped
- Due to funding decision by the sponsor
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Women or men with metastatic or inoperable, histologically confirmed breast cancer
- Has no alternative treatment of proven benefit available or has refused treatment
- Expected survival ≥ 3 months
- At least 2 measurable lesions according to RECIST 1.1, without contraindication for repeated injections and core needle biopsies
- Adequate organ function
- Eastern Cooperative Oncology Group performance status of 0 to 2
- Negative pregnancy test, if female
- Agreement to practice a highly effective method of contraception
- Agreement to no sperm donation through 28 days, if male
- Willing to provide consent to perform study procedures
Who cannot take part
- Anticancer therapy within 3 weeks of dosing
- Presence of a concurrent malignancy for which the natural history or treatment has the potential to interfere with the safety or efficacy assessment of the Investigational Product
- Immunodeficiency or use of therapies expected to impair the immune response within thirty (30) days of enrollment or during dosing
- Ongoing toxicity > Grade 1 from prior treatment except those which are stable
- Planned radiation to lesions targeted for assessment/injection within 60 days before first dose or any planned radiation during dosing period
- Uncontrolled or severe cardiovascular disease
- History of severe reaction (ie, anaphylaxis) to vaccination or immunotherapy
- Any condition or occupational or other responsibility that in the judgment of the Investigator would interfere with or serve as a contraindication to protocol adherence, assessment of safety, or a participant's ability to give informed consent
- Pregnant or lactating women
- Known active central nervous system metastases (with some exceptions)
Where in United States
- Dana-Farber Cancer InstituteBoston, United States
- Gabrail Cancer CenterCanton, United States
About the trial
What the trial wants to find out
The goal of this phase 1 open label clinical trial is to evaluate the safety and preliminary efficacy of CodaLytic, an intratumorally-administered oncolytic virus, in patients with metastatic or otherwise inoperable breast cancer.
Read full original descriptionShow less
The main questions it aims to answer are:
* How safe is CodaLytic when administered in escalating dosing groups into targeted lesions? * What is the impact of CodaLytic on lesion response and disease progression?
Eligible participants will be enrolled into four (4) escalating dose groups and treated with Codalytic through injection into a selected lesion(s) over twelve (12) weeks and then followed for up to one (1) year after the first dose. A safety committee will review the safety profile of each dosing group before the next dose-escalation.
Study procedures will include physical examinations, injection site assessments, biopsies, imaging, and collection of blood/urine to assess safety, the body's immune response, and efficacy.
The 4 groups in the trial
- 10e7 PFU dose 3 injectionsTreatment being tested
10e7 PFU CodaLytic administered intratumorally once every 4 weeks (3 doses total)
Treatment: CodaLytic
- 10e7 PFU dose 5 injectionsTreatment being tested
10e7 PFU CodaLytic administered intratumorally once every 2 weeks (5 doses total)
Treatment: CodaLytic
- 10e8 PFU dose 3 injectionsTreatment being tested
10e7 PFU CodaLytic administered intratumorally once every 4 weeks (3 doses total)
Treatment: CodaLytic
- 10e8 PFU dose 5 injectionsTreatment being tested
10e8 PFU CodaLytic administered intratumorally once every 2 weeks (5 doses total)
Treatment: CodaLytic
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Phase 1 Study of CodaLytic, an Intratumoral Influenza-based Oncolytic Virus, in Patients With Metastatic or Otherwise Inoperable Breast Cancer
- Record updated
- 18 October 2023